Ibere Pharmaceuticals (IBER)
NYSE: IBER
· Real-Time Price · USD
10.18
-0.02 (-0.20%)
At close: Mar 01, 2023, 9:58 PM
Company Description
Ibere Pharmaceuticals does not have significant operations.
It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses.
The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.
Ibere Pharmaceuticals
| Country | United States |
| IPO Date | n/a |
| Industry | Shell Companies |
| Sector | Financial Services |
| Employees | n/a |
| CEO | Osagie O. Imasogie |
Contact Details
Address: 2005 Market Street Philadelphia, Pennsylvania United States | |
| Website | https://www.iberepharma.com |
Stock Details
| Ticker Symbol | IBER |
| Exchange | NYSE |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001835205 |
| CUSIP Number | G46843101 |
| ISIN Number | n/a |
| Employer ID | 98-1564986 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Osagie O. Imasogie Esq. | Chairman & Chief Executive Officer |
| Lisa M. Gray CPA, CPA, CVA | Chief Financial Officer, Executive Vice President & Director |
| Zoltan Kerekes J.D. | Chief Operating Officer, Executive Vice President & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2023 | 15-12G | Filing |
| Mar 02, 2023 | 25-NSE | Filing |
| Feb 15, 2023 | 8-K | Current Report |
| Feb 14, 2023 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 08, 2023 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Feb 08, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 02, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2022 | 10-Q | Quarterly Report |
| Aug 12, 2022 | 10-Q | Quarterly Report |